On February 25, 2021, Kindred Biosciences, Inc. announcing its submission of efficacy data to the United States Department of Agriculture Center for Veterinary Biologics to support the prophylactic indication of KIND-030, a monoclonal antibody targeting canine parvovirus. This submission is part of the overall project data package that will be submitted and evaluated for full approval. KIND-030 is a monoclonal antibody targeting canine parvovirus. On September 16, 2020, KindredBio reported positive results from its pivotal efficacy study for the prophylactic indication. As previously stated, approval of KIND-030 is subject to regulatory risk and timelines, and there is no set review timeline at the USDA Center for Veterinary Biologics. Regulatory consultants to KindredBio anticipate possible delays to the regulatory review process due to COVID-19. KindredBio will provide an update on the timing of KIND-030's expected approval at the time of announcing the company's fourth quarter 2020 results. Regulatory approval and review timeline are subject to the typical risks inherent in such a process. KIND-030 is being pursued for two indications in dogs prophylactic therapy to prevent clinical signs of canine parvovirus infection, and treatment of established parvovirus infection. Completion of the upcoming pivotal efficacy study for the treatment indication for KIND-030 is now expected to extend into the second quarter of 2021. KindredBio does not expect the updated timing of completion of the pivotal efficacy study for the treatment indication to impact achievement of the terms contained in the parvovirus license agreement with Elanco Animal Health Incorporated.